New advances in Parkinson's research and treatment

10/11/05

Science reporters briefing

WHAT:
The National Institute of Neurological Disorders and Stroke (NINDS) in partnership with the Parkinson's community is bringing together a panel of leading physicians, scientists, and caregivers to provide an overview of the newest advances in Parkinson's disease. Researchers will discuss genetic aspects of the disease, new approaches to therapeutics, and environmental and other factors that may impact onset of Parkinson's. Panelists will discuss their work and respond to questions from the audience.

WHY:
After Alzheimer's disease, Parkinson's is the most common neurodegenerative disorder. There are an estimated 6.3 million people worldwide suffering from Parkinson's disease. Because of the aging world population, and given that the number of older Americans will more than double to 70 million by 2030, now is the time to begin gaining a better understanding of diseases, such as Parkinson's, that have a significant impact on older adults..

WHO:
Experts in Parkinson's disease will make brief remarks. A session for questions and answers will follow each speaker.

Story Landis, Ph.D., Director, NINDS

J. Timothy Greenamyre, M.D., Ph.D., University of Pittsburgh Medical Center, Environmental Influences and Parkinson's Disease (PD)

Robert L. Nussbaum, M.D., National Human Genome Research Institute, Genetics of PD

Peter T. Lansbury, Jr., Ph.D., Brigham and Women's Hospital, Drug Discovery for PD

Clive Svendsen, M.D., University of Wisconsin-Madison, Future Therapeutic Approaches

Monique Giroux, M.D., The Cleveland Clinic Foundation, Caring for Patients with PD Across the Clinical Spectrum

Morton Kondracke, Author of Saving Milly, Caregiver's Perspective

WHEN:
Thursday, October 20, 2005, 10:00 AM ET

WHERE:
The Dana Center, 900 15th St, NW, Washington, DC

Source: Eurekalert & others

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.

 

 

The life which is unexamined is not worth living.
~ Plato